Skip to Main Content

We have a new app!

Take the Access library with you wherever you go—easy access to books, videos, images, podcasts, personalized features, and more.

Download the Access App here: iOS and Android

Inborn error of metabolism that leads to isolated hyperglycinemia.

Glycine Encephalopathy; Glycinemia.

1:250,000 live births; most cases are from Finland (1:12,000 live births).

Autosomal recessive.

Defect in enzymes of the hepatic glycine cleavage system leads to accumulation of glycine. The system is composed of four mitochondrial proteins known as P, H, T, and L, and catalyzes the transformation of glycine in CO2, ammonia, and hydroxymethyltetrahydrofolic acid. Elevation of glycine levels in the brain is thought to be responsible for the clinical symptoms of the disease: glycine is an inhibitory neurotransmitter at the level of the brainstem and spinal cord but has excitatory effects on the cerebral cortex.

Elevated levels of glycine in plasma, cerebrospinal fluid, and urine with no ketosis. Defect of enzyme system may be demonstrated in liver biopsy specimen or prenatally in cultured chorionic villi.

Three clinical presentations exist.

Neonatal Type: Most common presentation. After a few days (rarely more than 48 hours), the neonate presents with rapidly progressing neurologic symptoms: hypotonia, apneic attacks, seizures, lethargy, or coma. Seizures range from myoclonic to grand mal convulsions and are often accompanied by hiccup. A characteristic burst-suppression pattern is seen on electroencephalogram (EEG) during the first month and is later replaced by hypsarrhythmia. Death frequently occurs during infancy or childhood. Survivors have mental retardation, myoclonus, seizures, and microcephaly.

Late-Inset Type: Nonspecific neurologic symptoms develop during infancy to adolescence.

Transient Neonatal Type: High neonatal plasma and cerebrospinal fluid (CSF) levels of glycine return to normal after a few weeks. Immaturity of one of the components of the glycine cleavage system is postulated to be the cause of this transient disease.

There is no effective treatment. Antagonists of N-methyl-d-aspartate (NMDA) receptors, such as oral ketamine (8 mg/kg/day) or dextromethorphan, have been used with some success. Oral benzoate (500-750 mg/kg/day) complexes with glycine to form hippuric acid, which undergoes renal elimination. Benzodiazepines are indicated for seizures.

Ensure adequate hydration and calorific intake. Assess neurologic status.

Surgery may be associated with acute deterioration. Adequate hydration and caloric input should be maintained perioperatively.

Ketamine appears to be a good choice because of its NMDA receptor antagonist properties.

Ohtahara Syndrome: Congenital epileptiform encephalopathy with typical EEG pattern of burst-break suppression awake and asleep. Onset in the first month of life; frequent tonic seizures and severe developmental delay; poor prognosis; usual evolution to infantile spasms.

Sami KA: Non-ketotic hyperglycinaemias. Can Anaesth Soc J 27:79, 1980.  [PubMed: 7353195]
Tada K: Nonketotic hyperglycinemia, in Fernades J, Saudubray J-M, van den Berghe G (eds): Inborn Metabolic Diseases. 3rd ed. Berlin, Springer, 2000, p 254.

Pop-up div Successfully Displayed

This div only appears when the trigger link is hovered over. Otherwise it is hidden from view.